Hebei Rimao Technology Safety Rating & Test Results
As of 25 Jul 2026, Finnrick has published 54 independent lab tests of 5 peptides from Hebei Rimao Technology: 40 passed and 14 failed under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 26 Jun 2026.
Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.
Purchased from Hebei Rimao Technology? Submit a sample to Finnrick for free independent lab testing — results are published publicly.
Are you Hebei Rimao Technology? Finnrick offers professional testing services and a public launch program for peptide vendors.
Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.
| Peptide | Finnrick rating | Lab tests | Latest test |
|---|---|---|---|
| BPC-157 | 49% | 6 | 4 Mar 2026 |
| GHK-Cu | 92% | 5 | 23 Apr 2026 |
| Retatrutide | 84% | 21 | 26 Jun 2026 |
| Tesamorelin | 49% | 5 | 6 May 2026 |
| Tirzepatide | 70% | 17 | 26 Jun 2026 |